hrcak mascot   Srce   HID

Ostalo

MANAGEMENT OF SIDE EFFECTS INDUCED BY ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS INFECTION

MARTINA SMOLIĆ ; Josip Juraj Strossmayer University, School of Medicine, Chair of Pharmacology, Osijek, Croatia
ROBERT SMOLIĆ ; Josip Juraj Strossmayer University, School of Medicine, Chair of Pharmacology, and School of Medicine, Osijek University Hospital Center, Clinical Department of Internal Medicine, Osijek, Croatia
ALEKSANDAR VČEV ; Josip Juraj Strossmayer University, School of Medicine, Chair of Pharmacology, and School of Medicine, Osijek University Hospital Center, Clinical Department of Internal Medicine, Osijek, Croatia

Puni tekst: hrvatski, pdf (103 KB) str. 383-387 preuzimanja: 895* citiraj
APA 6th Edition
SMOLIĆ, M., SMOLIĆ, R. i VČEV, A. (2013). LIJEČENJE NUSPOJAVA ANTIVIRUSNE TERAPIJE KRONIČNIH HEPATITISA. Acta medica Croatica, 67 (4), 383-387. Preuzeto s https://hrcak.srce.hr/113727
MLA 8th Edition
SMOLIĆ, MARTINA, et al. "LIJEČENJE NUSPOJAVA ANTIVIRUSNE TERAPIJE KRONIČNIH HEPATITISA." Acta medica Croatica, vol. 67, br. 4, 2013, str. 383-387. https://hrcak.srce.hr/113727. Citirano 03.12.2020.
Chicago 17th Edition
SMOLIĆ, MARTINA, ROBERT SMOLIĆ i ALEKSANDAR VČEV. "LIJEČENJE NUSPOJAVA ANTIVIRUSNE TERAPIJE KRONIČNIH HEPATITISA." Acta medica Croatica 67, br. 4 (2013): 383-387. https://hrcak.srce.hr/113727
Harvard
SMOLIĆ, M., SMOLIĆ, R., i VČEV, A. (2013). 'LIJEČENJE NUSPOJAVA ANTIVIRUSNE TERAPIJE KRONIČNIH HEPATITISA', Acta medica Croatica, 67(4), str. 383-387. Preuzeto s: https://hrcak.srce.hr/113727 (Datum pristupa: 03.12.2020.)
Vancouver
SMOLIĆ M, SMOLIĆ R, VČEV A. LIJEČENJE NUSPOJAVA ANTIVIRUSNE TERAPIJE KRONIČNIH HEPATITISA. Acta medica Croatica [Internet]. 2013 [pristupljeno 03.12.2020.];67(4):383-387. Dostupno na: https://hrcak.srce.hr/113727
IEEE
M. SMOLIĆ, R. SMOLIĆ i A. VČEV, "LIJEČENJE NUSPOJAVA ANTIVIRUSNE TERAPIJE KRONIČNIH HEPATITISA", Acta medica Croatica, vol.67, br. 4, str. 383-387, 2013. [Online]. Dostupno na: https://hrcak.srce.hr/113727. [Citirano: 03.12.2020.]

Sažetak
Recently approved direct-acting antiviral agents (DAA) for the treatment of chronic infection with hepatitis C virus (HCV) genotype 1, protease inhibitors (PI) boceprevir and telaprevir, have substantially increased the rates of sustained virologic response in the treatment of naïve and experienced patients. However, triple therapy came with a burden of a new spectrum of side effects, which may lead to dose reduction and even discontinuation of therapy. Anticipating the adverse events of PIs, informing patients about their risk and manage them appropriately and efficiently is important for safe and successful treatment outcome. Anemia, although not the most common side effect, has emerged as the most significant one. Effective management of anemia includes close monitoring of complete blood count, extensive ribavirin dose reductions, and possible addition of erythropoietin or blood transfusions. In patients on triple therapy, if RBV is stopped for 7 days or more, the PI should also be permanently discontinued. Dose reductions of HCV PIs are not allowed; the HCV PIs are either administered at full dose or discontinued. Successful adherence to treatment can be enhanced by timely informing the patient that most treatment-related adverse effects can be minimized and managed.

Ključne riječi
side effects; protease inhibitors; pegylated interferon; nucleoside analogues; hepatitis C virus

Hrčak ID: 113727

URI
https://hrcak.srce.hr/113727

[hrvatski]

Posjeta: 1.231 *